Literature DB >> 18688585

[Vitamin D and the skin].

M Hösl1, M Berneburg.   

Abstract

Along with other organs like prostate, bones and kidney, skin is capable of vitamin D synthesis. Primarily keratinocytes but also macrophages and fibroblasts synthesize active vitamin D from cholesterol precursors by photochemical activation. The synthesized vitamin D functions by binding to nuclear vitamin D receptors. Vitamin D deficiency usually manifests as rickets in childhood although it is today only relevant in diseases characterized by malabsorption due to today's recommended vitamin D prophylaxis. Excessive doses of vitamin D are the usual cause of increased levels. The most common therapeutic target of Vitamin D is psoriasis. Here, topical preparations are usually employed; their anti-proliferative and cell differentiation-promoting action is mediated via binding to cutaneous vitamin D receptors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18688585     DOI: 10.1007/s00105-008-1499-x

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  19 in total

1.  Transcriptional profiling of keratinocytes reveals a vitamin D-regulated epidermal differentiation network.

Authors:  Jianfen Lu; Keith M Goldstein; Peining Chen; Shuguang Huang; Lawrence M Gelbert; Sunil Nagpal
Journal:  J Invest Dermatol       Date:  2005-04       Impact factor: 8.551

2.  Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study.

Authors:  C F Garland; G W Comstock; F C Garland; K J Helsing; E K Shaw; E D Gorham
Journal:  Lancet       Date:  1989-11-18       Impact factor: 79.321

3.  UVB-induced conversion of 7-dehydrocholesterol to 1alpha,25-dihydroxyvitamin D3 in an in vitro human skin equivalent model.

Authors:  B Lehmann; T Genehr; P Knuschke; J Pietzsch; M Meurer
Journal:  J Invest Dermatol       Date:  2001-11       Impact factor: 8.551

4.  Demonstration of UVB-induced synthesis of 1 alpha,25-dihydroxyvitamin D3 (calcitriol) in human skin by microdialysis.

Authors:  B Lehmann; W Sauter; P Knuschke; S Dressler; M Meurer
Journal:  Arch Dermatol Res       Date:  2003-03-11       Impact factor: 3.017

5.  A plea for the analysis of Vitamin-D levels in patients under photoprotection, including patients with xeroderma pigmentosum (XP) and basal cell nevus syndrome (BCNS).

Authors:  K Querings; J Reichrath
Journal:  Cancer Causes Control       Date:  2004-03       Impact factor: 2.506

6.  Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial.

Authors:  L Guenther; P C M Van de Kerkhof; E Snellman; K Kragballe; A C Chu; E Tegner; A Garcia-Diez; J Springborg
Journal:  Br J Dermatol       Date:  2002-08       Impact factor: 9.302

7.  Molecular pathways involved in the anti-apoptotic effect of 1,25-dihydroxyvitamin D3 in primary human keratinocytes.

Authors:  Petra De Haes; Marjan Garmyn; Geert Carmeliet; Hugo Degreef; Katleen Vantieghem; Roger Bouillon; Siegfried Segaert
Journal:  J Cell Biochem       Date:  2004-11-15       Impact factor: 4.429

Review 8.  Evolution and function of vitamin D.

Authors:  Michael F Holick
Journal:  Recent Results Cancer Res       Date:  2003

9.  Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis.

Authors:  Kim A Papp; Lyn Guenther; Bernard Boyden; Frederik Grønhøj Larsen; Rauno J Harvima; Jean Jacques Guilhou; Roland Kaufmann; Sarah Rogers; Peter C M van de Kerkhof; Leif I Hanssen; Eva Tegner; Günter Burg; David Talbot; Anthony Chu
Journal:  J Am Acad Dermatol       Date:  2003-01       Impact factor: 11.527

10.  Analysis of the vitamin D system in cutaneous squamous cell carcinomas.

Authors:  Jörg Reichrath; Leyla Rafi; Martin Rech; Tanja Mitschele; Viktor Meineke; Barbara C Gärtner; Wolfgang Tilgen; Michael F Holick
Journal:  J Cutan Pathol       Date:  2004-03       Impact factor: 1.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.